Condition: APL · Sponsor: Shanghai Jiao Tong University School of Medicine
Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment. In our pre-clinical study, we found that targeting histone deacetylase inhibitor 3 (HDAC3)degraded PML-RARa oncoprotein and induced differentiation and apoptosis of RA and As resistant APL in vitro and in vivo. In this study, we evaluate the efficacy and feasibility of combination therapy for HDAC3 inhibitor and venetoclax in patients with refractory APL.
This description comes directly from the study's public registry record.
Chun Wang, M.D., · 8613386259777 · wangchunsh@medmail.com.cn
Always discuss trial participation with your own doctor first.
| The Affiliated Huai An No 1 Perople's Hospital of NanJing University | Huai'an, Jiangsu, China | Not Yet Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Not Yet Recruiting |
| Jiong HU | Shanghai, Shanghai Municipality, China | Recruiting |
| Zhaxin Hospital, Go Broad Health Care | Shanghai, Shanghai Municipality, China | Active Not Recruiting |
| NanFang Hospital | Guangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05881265